

New β -Caryophyllene-Derived Terpenoids from the Soft Coral *Sinularia nanolobata*

Atallah F. Ahmed,^{†,‡} Jui-Hsin Su,[†] Ru-Ting Shiue,[†] Xin-Jie Pan,[†] Chang-Feng Dai,[§] Yao-Haur Kuo,[⊥] and Jyh-Horng Sheu^{*†}

Department of Marine Resources, National Sun Yat-Sen University, Kaohsiung 804, Taiwan, Republic of China, Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt, Institute of Oceanography, National Taiwan University, Taipei 106, Taiwan, Republic of China, and National Research Institute of Chinese Medicine, Taipei 112, Taiwan, Republic of China

Received June 26, 2003


Two new norsesquiterpenoids, nanonorcaryophyllenes A (**1**) and B (**2**), two new diterpenoids, nanolobatins A (**3**) and B (**4**), and a novel norditerpenoid, nanolobatin C (**5**), were isolated from the *n*-hexane extract of the Taiwanese soft coral *Sinularia nanolobata*. Also, two new furanone derivatives, **6** and **7**, were isolated for the first time from natural sources. The structures of **1–5** were elucidated on the basis of extensive spectroscopic analyses and by comparison of the spectral data with those of the related metabolites. Nanonorcaryophyllenes A (**1**) and B (**2**) were characterized as 13-norcaryophyllenes that lack a methyl group at C-11, while nanolobatin C (**5**) represents the first example of a xeniaphyllane-based 17-norditerpenoid. The cytotoxicity of **1–6** against the growth of a limited panel of cancer cell lines is also described.

Soft corals belonging to genus *Sinularia* (Alcyoniidae) have been found to be a rich source of structurally unique and biologically active diterpenoids¹ and norditerpenoids.^{1,2} A previous study on a Japanese sample of *Sinularia nanolobata* Verseveldt resulted in the isolation of several cytotoxic amphilectane-type diterpenoids, sinulobatins.³ During the course of our screening of bioactive metabolites from marine organisms,^{2,4–7} an investigation on the chemical constituents of *S. nanolobata* from Taiwanese waters has afforded two xeniaphyllane-type⁸ diterpenoids, nanolobatins A (**3**) and B (**4**). A novel norditerpenoid, nanolobatin C (**5**), has also been isolated and identified as the first 17-norxeniaphyllane. Although xeniaphyllanes have been known as the secondary metabolites of soft corals of *Xenia*,⁹ *Nephthea*,⁸ and *Cespitularia*,¹⁰ this is the first report on metabolites of this type from the genus *Sinularia*. Furthermore, two norsesquiterpenes, nanonorcaryophyllenes A (**1**) and B (**2**), and two furanone derivatives, **6** and **7**, were also isolated in the present study. The structures of **1–5** were elucidated on the basis of extensive spectroscopic analyses, and their relative stereochemistries were deduced by the assistance of NOESY experiments and by comparison of the NMR data with those of related xeniaphyllane and β -caryophyllene-derived metabolites.^{8–16}

In addition to the isolation and structural elucidation of these compounds, *in vitro* cytotoxic activities of metabolites **1–6** against KB (human oral epidermoid carcinoma), Hepa59T/VGH (human liver carcinoma), NCI-H661 (human lung large cell carcinoma), Hela (human cervical epitheloid carcinoma, DLD-1 (human colon adenocarcinoma), and Med (human medulloblastoma) cell lines also have been evaluated.

Results and Discussion

The minced tissues of *S. nanolobata* were successively extracted with *n*-hexane and dichloromethane. The residue



* To whom correspondence should be addressed. Tel: 886-7-5252000, ext. 5030. Fax: 886-7-5255020. E-mail: sheu@mail.nsysu.edu.tw.

[†] National Sun Yat-Sen University.

[‡] Mansoura University.

[§] National Taiwan University.

[⊥] National Research Institute of Chinese Medicine.

of the dichloromethane layer was further extracted with *n*-hexane. The combined *n*-hexane extract was concen-

Table 1. ^{13}C NMR Chemical Shifts of Compounds **1**–**5**, **8**,¹¹ and **14**¹²

no.	1 ^a	2 ^a	3 ^a	4 ^a	5 ^b	8 ^c	14 ^{d,e}
1	53.7 (CH) ^f	56.1 (CH)	49.8 (CH)	45.3 (CH)	45.3 (CH)	50.8 (CH)	47.7* (CH)
2	26.5 (CH ₂)	26.5 (CH ₂)	27.9 (CH ₂)	28.2 (CH ₂)	28.0 (CH ₂)	27.2 (CH ₂)	29.8** (CH ₂)
3	38.9 (CH ₂)	30.8 (CH ₂)	39.1 (CH ₂)	38.6 (CH ₂)	38.5 (CH ₂)	39.1 (CH ₂)	38.5 (CH ₂)
4	59.9 (C)	48.0 (CH)	59.9 (C)	59.6 (C)	59.4 (C)	59.8 (C)	59.5 (C)
5	63.9 (CH)	217.0 (C)	63.9 (CH)	63.7 (CH)	63.6 (CH)	63.7 (CH)	63.5 (CH)
6	30.3 (CH ₂)	42.2 (CH ₂)	30.2 (CH ₂)	30.1 (CH ₂)	30.0 (CH ₂)	30.2 (CH ₂)	29.7** (CH ₂)
7	29.2 (CH ₂)	32.1 (CH ₂)	29.8 (CH ₂)	29.7 (CH ₂)	29.5 (CH ₂)	29.8 (CH ₂)	35.1** (CH ₂)
8	150.5 (C)	151.7 (C)	151.8 (C)	150.8 (C)	150.6 (C)	151.8 (C)	150.4 (C)
9	44.9 (CH)	39.7 (CH)	48.8 (CH)	47.3 (CH)	47.2 (CH)	48.7 (CH)	47.3* (CH)
10	42.6 (CH ₂)	41.9 (CH ₂)	38.6 (CH ₂)	35.3 (CH ₂)	35.1 (CH ₂)	39.8 (CH ₂)	27.5** (CH ₂)
11	71.1 (C)	71.0 (C)	36.0 (C)	47.8 (C)	48.2 (C)	34.0 (C)	41.8 (C)
12	21.5 (CH ₃)	21.3 (CH ₃)	44.4 (CH ₂)	203.7 (C)	213.1 (C)	29.9 (CH ₃)	182.8 (C)
13			22.4 (CH ₂)	120.2 (CH)	32.5 (CH ₂)	21.6 (CH ₃)	16.8*** (CH ₃)
14	113.9 (CH ₂)	112.2 (CH ₂)	128.9 (CH)	153.6 (CH)	29.6 (CH ₂)	112.7 (CH ₂)	114.0 (CH ₂)
15	17.1 (CH ₃)	16.7 (CH ₃)	134.1 (C)	71.2 (C)	70.3 (CH)	17.0 (CH ₃)	16.4*** (CH ₃)
16			61.6 (CH ₂)	29.6 (CH ₃)	20.2 (CH ₃)		
17			21.3 (CH ₃)	29.6 (CH ₃)			
18			18.9 (CH ₃)	17.0 (CH ₃)	16.8 (CH ₃)		
19			113.0 (CH ₂)	115.0 (CH ₂)	114.1 (CH ₂)		
20			17.1 (CH ₃)	17.1 (CH ₃)	17.0 (CH ₃)		
Ac					170.7 (C)		
					21.3 (CH ₃)		

^a Spectra recorded at 75 MHz in CDCl₃ at 25 °C. ^b 125 MHz in CDCl₃ at 25 °C. ^c 100 MHz in CDCl₃, see ref 11. ^d 75.5 MHz in CDCl₃. ^e *, **, ***Assignments of chemical shifts may be exchanged between shifts indicated by the same superscript, see ref 12. ^f Multiplicity deduced by DEPT and indicated by usual symbols. The values are in ppm downfield from TMS.

Table 2. ^1H NMR Chemical Shifts of Compounds **1**, **2**, and **8**

	1 ^a	2 ^a	8 ^{b,11}
H-1	2.07 t (10.0) ^c	1.68 m	1.76 t (10.0)
H-2 α	1.88 m	1.24 dd (15.0, 8.4)	1.32 m
H-2 β	1.43 m	1.82 d (15.0)	1.55–1.72 m
H-3 α	1.04 dt (4.8, 13.0)	1.80 t (9.3)	0.95 m
H-3 β	2.10 m	1.65 m	2.10 dt (3.5, 12.5)
H-4		2.54 m	
H-5	2.89 dd (10.5, 3.6)		2.87 dd (10.6, 4.1)
H-6 α	2.25 dt (12.0, 3.5)	2.50–2.54 m	1.42 m
H-6 β	1.34 m	2.50–2.54 m	2.25 ddd (16.4, 7.8, 4.1)
H-7 α	2.35 ddd (12.3, 6.0, 3.3)	2.42–2.50 m	2.11 t (12.4)
H-7 β	2.14 m	2.42–2.50 m	2.34 ddd (12.4, 8.1, 4.4)
H-9	2.15 m	1.89 dt (7.5, 9.3)	2.61 q (10.0)
H-10 α	2.02 dd (10.2, 7.5)	1.77 t (9.6)	1.55–1.72 m
H-10 β	1.88 m	2.07 dd (9.6, 7.5)	1.55–1.72 m
H-12	1.25 3H, s	1.16 3H, s	0.98 3H, s
H-13			1.00 3H, s
H-14	4.90 1H, s	4.93 2H, s	4.85 s
	5.00 1H, s		4.97 s
H-15	1.19 3H, s	1.04 3H, d (6.9)	1.20 3H, s

^a Spectra recorded at 300 MHz in CDCl₃ at 25 °C. ^b 400 MHz in CDCl₃, see ref 11. ^c The *J* values (in parentheses) are in Hz.

trated, and the residue was subjected to column chromatography over silica gel. Five fractions obtained were chosen for further purification by normal-phase HPLC to yield nanonorcaryophyllenes A (**1**) and B (**2**), nanolobatin A–C (**3**–**5**), and the furanone derivatives **6** and **7** (see Experimental Section).

Nanonorcaryophyllene A (**1**) possesses the molecular formula C₁₄H₂₂O₂ as revealed by its HREIMS (*m/z* 222.1617, [M]⁺) and NMR spectral data (Tables 1 and 2). Thus, **1** possesses four degrees of unsaturation. The infrared spectrum and MS data revealed the presence of a hydroxyl group in **1** (ν_{max} 3371 cm⁻¹ and *m/z* 204 [M – H₂O]⁺). From the 14 carbon signals appearing in the ^{13}C NMR spectrum of **1**, two methyls (δ 17.1 and 21.5), one trisubstituted epoxide (δ 59.9, C and 63.9, CH), one double bond containing an exomethylene group (δ 113.9, CH₂ and 150.5, C), and two methines (δ 44.9 and 53.7) could be assigned. Due

to the presence of two sp² carbon resonances in the ^{13}C NMR spectrum of **1** for one carbon–carbon double bond, **1** was considered to be a tricyclic compound. By the assistance of extensive 2D NMR study (COSY, HMQC, and HMBC), the norcaryophyllene-based skeleton of **1** was proposed (Figure 1). Also, comparison of the ^1H and ^{13}C NMR spectral data of **1** with those of **8**¹¹ (Tables 1 and 2) revealed that a methyl substituent at C-11 in **8** was replaced by a hydroxyl group in **1**. Thus, the norsequiterpenoid nature of **1** was fully established. The relative stereochemistry of **1** (Figure 2) was proposed on the basis of the key NOE correlations observed in the NOESY spectrum. Furthermore, it was found that the spectral data of (1*R*,4*R*,5*R*,9*S*,11*R*)-4,5-epoxy-12-nor-8(14)-caryophyllen-11-ol (**12**),¹² obtained previously by a microbial biotransformation of β -caryophyllene, were almost identical in all aspects with those of **1** except the sign of optical rotation. Nanocaryophyllene A (**1**) ([α]_D +42.6°) was thus enantiomeric with **12** ([α]_D –36.3°), and the absolute structure of **1** was established as (1*S*,4*S*,5*S*,9*R*,11*S*)-4,5-epoxy-12-nor-8(14)-caryophyllen-11-ol.

Nanonorcaryophyllene B (**2**) has the same molecular formula, C₁₄H₂₂O₂, as that of **1**, as revealed from the HREIMS (*m/z* 222.1618, [M]⁺) and NMR spectral data (Tables 1 and 2). The existence of a ketone functional group (ν_{max} 1700 cm⁻¹) and a hydroxyl moiety (ν_{max} 3422 cm⁻¹ and *m/z* 204 [M – H₂O]⁺) in **2** could be observed. The ^{13}C NMR spectrum also revealed that **2** is a norcaryophyllene-based metabolite. Comparison of ^{13}C NMR spectral data of **2** and **1** (Table 1) indicated that the two carbons of the trisubstituted epoxide (δ 59.9, C and 63.9, CH) in **1** were replaced by a methine (δ 48.0) and a ketone carbonyl (δ 217.0, C) carbon. The proton resonating at δ 2.54 (1H, m) that showed COSY correlations (Figure 1) with the signals of a secondary methyl at δ 1.04 (3H, d, *J* = 6.9 Hz) and H₂-3 (δ 1.65, m; 1.80, t, *J* = 9.3 Hz) was designated as H-4. Furthermore, the HMBC correlations of H-4, H₃-15, H₂-3, H₂-6, and H₂-7 with the carbon signal at δ 217.0 ppm revealed the ketone functionality of C-5. On the basis of the above findings and key COSY and HMBC correlations observed (Figure 1), the skeleton of **2** could be established unambiguously.




Figure 1. ^1H - ^1H COSY and HMBC correlations for **1**-**6**.




Figure 2. Key NOESY correlations of **1** and **2**.

The relative stereochemistry of **2** (Figure 2) was deduced from the NOE interactions observed in the NOESY spectrum and by comparison of its ^1H and ^{13}C spectral data with those of the related compounds (**9** and **11**).¹³⁻¹⁶ Assuming the β -orientation of H-1, it was found that H-1 exhibited a weak but meaningful NOE correlation with H-4 (δ 2.54, m). This observation is consistent with H-4 being located on the β face. Also, H-1 exhibited NOE correlation with the β -proton at C-2 (δ 1.82, d, J = 15.0 Hz), which in turn showed interaction with H- 3β (δ 1.65, m), while the




Figure 3. Key NOESY correlations of **3** and **5**.

latter further correlated with H-4. Thus, the β -orientation of H-4 could be established unambiguously. H-1 was also found to exhibit significant NOE interactions with H₃-12 (δ 1.16, 3H, s) and H-9 (δ 1.89, dt, J = 7.5, 9.3 Hz), implying the β -orientations of H-9 and the methyl substituent at C-11. On the basis of the above findings and other key NOE interactions observed, the *cis* ring junction at C-1 and C-9 in **2** was established. Since only a few 9-*epi*- β -caryophyllenes have been isolated from nature,¹³⁻¹⁷ further confirmation of the configuration at the ring junction was sought. It was found that a *cis* configuration of the ring junction (as in **9** and **11**) induces an upfield shift at C-9 by almost more than 5.0 ppm relative to the corresponding *trans* isomers (as in the cases of **8** and **10**).¹³ Because the C-9 of **2** showed a signal at δ 39.7 ppm, which is found to be upfield shifted by 5.2 and 6.0 ppm, respectively, in comparison to those of the related norsesquiterpenoids **1** ($\delta_{\text{C-9}}$ = 44.9 ppm) and **13** ($\delta_{\text{C-9}}$ = 45.7 ppm),¹⁸ the *cis* ring junction in **2** was established unambiguously. Although at this stage we do not have sufficient data for determination of the absolute configuration, the relative stereochemistry of nanonorcaryophyllene B (**2**) could be fully assigned as (1*R**,4*S**,9*R**,11*S**)-5-oxo-13-nor-8(14)-caryophyllen-11-ol on the basis of the above findings.

The new metabolite nanolobatin A (**3**) was obtained as a colorless oil. The molecular formula of **3** was established as $\text{C}_{20}\text{H}_{32}\text{O}_2$ by HREIMS (m/z 304.2404, $[\text{M}]^+$), thus requiring five degrees of unsaturation. The presence of a hydroxyl group in **3** was revealed from the absorption band at 3437 cm^{-1} and the ion peak at m/z 286 $[\text{M} - \text{H}_2\text{O}]^+$ in the IR and EIMS spectra, respectively. The ^{13}C NMR spectrum of **3** showed signals of 20 carbons (Table 1), among which 11 carbons have very similar chemical shifts in comparison with those of the ring carbons (C-1 to C-11) of **8**, suggesting that **3** could be a caryophyllene-related diterpenoid. Detailed analyses of 2D NMR spectra of **3**, focusing in particular on the interpretation of ^1H - ^1H COSY, HMQC, and HMBC correlations, illustrated the gross structure of **3** as shown in Figure 1. Thus, the structure of **3** was determined to be consistent with a metabolite possessing a 4,5-epoxyxeniaphyllane skeleton.

The relative stereochemistry of **3** was determined on the basis of the NOE correlations observed in a NOESY spectrum (Figure 3). Assuming the α -orientation of H-1, it was found that H-1 exhibited strong NOE interaction with

H-5, indicating the α -orientation of H-5. One proton attached at C-3 and resonating at δ 0.94 (dt, $J = 6.0, 14.4$ Hz) showed NOE correlation with H-5 and was assigned as H-3 α . The other proton attached at C-3, H-3 β (δ 2.06, m), displayed NOE correlation with H₃-20, which further interacted with H-9, revealing the β -orientations of H-9 and H₃-20. H₃-18 showed NOE interaction with H-9, but not with H-1, and should be positioned on the β face. Furthermore, the NOE correlations displayed between the H-14 and H₃-17 revealed the *Z* geometry of the 14,15-double bond. Therefore, the relative structure of nanolobatin A (**3**) was unambiguously established as in formula **3**. As compound **3** ($[\alpha]_D +15.0^\circ$) is the prenylated derivative of **1** ($[\alpha]_D +42.6^\circ$) and both are isolated from the same organism, it is reasonable to assign the same absolute configuration at C-1, C-4, C-5, C-9, and C-11 for **3** as that of **1**. The structure of nanolobatin A (**3**) was thus determined as (1*S*,4*S*,5*S*,9*R*,11*S*,14*Z*)-4,5-epoxyxeniaphylla-8(19),14-dien-16-ol.

The second related diterpenoid metabolite, nanolobatin B (**4**), was also obtained as a colorless oil. Its HREIMS spectral data (m/z 318.2394) suggested the molecular formula C₂₀H₃₀O₃, requiring six degrees of unsaturation. The infrared absorption band at 3640 cm⁻¹ indicated the presence of a hydroxyl group. Comparison of ¹³C NMR spectral data of **4** with those of **3** (Table 1) revealed that **4** should be another xeniaphyllene-type diterpenoid and differs from **3** only in the isoprene tail (C-12 to C-18) portion of the molecule. It was found that **4** possesses a ketone carbonyl (δ 203.7, C), a 1,2-disubstituted carbon-carbon double bond (δ 120.2, CH and 153.6, CH), and a carbon containing a tertiary hydroxyl group (δ 71.2, C). The downfield shift exerted at C-11 (δ 47.8, C) of **4** relative to that of **3** (δ 36.0, C) allowed C-12 to be assigned to the ketone carbonyl, as the similar magnitude of this downfield shift also was observed on comparison of ¹³C NMR data of the known compounds **8**¹¹ and **14**¹² (Table 1). The *E*-1,2-disubstituted double bond was revealed by the signals of two vicinal protons (δ 6.41, 1H, d, $J = 15.3$ Hz; δ 6.97, 1H, d, $J = 15.3$ Hz). On the basis of the above observations and other key COSY and HMBC correlations (Figure 1), the molecular framework of **4** was established. Comparison of chemical shifts and *J* values of H-1, H-5, and H-9 and chemical shifts of C-1, C-4, C-5, C-9, and C-11 of **4** with those of **3** and **5** (discussed later) indicated that **3**–**5** possess the same relative stereochemistries at C-1, C-4, C-5, C-9, and C-11. By comparison with one of the fermentation products of β -caryophyllene, (1*R*,4*R*,5*R*,9*S*,11*R*)-4,5-epoxycaryophyll-8(14)-en-12-ol-ic acid (**14**)¹² ($[\alpha]_D -55.5^\circ$), the prenylated derivative nanolobatin B (**4**) ($[\alpha]_D +66.7^\circ$) was finally defined as (1*S*,4*S*,5*S*,9*R*,11*S*,13*E*)-4,5-epoxyxeniaphylla-8(19),13-dien-12-on-15-ol, on the basis of the signs of optical rotations of these two compounds.

The novel norditerpene nanolobatin A (**5**) was isolated from a less polar fraction of the hexane extract. A molecular formula of C₂₁H₃₂O₄ for **5** was suggested by the FABMS spectrum of **5**, which exhibited a peak at m/z 349 [M + H]⁺, and ¹³C and ¹H NMR spectral data (Tables 1 and 3). The HREIMS spectrum showed a strong ion peak at m/z 288.2084, which corresponds to a fragment with a molecular formula C₁₉H₂₈O₂ arising from the elimination of an equivalent of acetic acid. Infrared absorption bands at 1734 and 1700 cm⁻¹ indicated that **5** possesses ester and ketone functionalities. Comparison of the ¹³C NMR spectral data of **5** with those of **4** (Table 1) indicated that **5** has the same carbon skeleton as that of **4** from C-1 to C-12, while the 13,14-double bond in **4** was reduced. In addition to the presence of an acetate methyl group which showed a signal

Table 3. ¹H NMR Chemical Shifts of Compounds **3**–**5**

	3 ^a	4 ^a	5 ^b
H-1	1.83 t (9.6) ^c	2.46 t (9.7)	2.41 t (10.0)
H-2 α	1.65 m	1.85 (10.8, 8.7)	1.77 dd (14.5, 3.0)
H-2 β	1.43 m	1.57 m	1.54 ddd (14.5, 10.5, 4.0)
H-3 α	0.94 dt (6.0, 14.4)	1.12 dt (4.8, 14.0)	1.07 dt (5.0, 13.0)
H-3 β	2.06 m	2.10 m	2.10 d (13.0)
H-5	2.88 dd (10.5, 3.9)	2.91 dd (10.5, 4.0)	2.90 dd (10.5, 4.0)
H-6 α	2.25 m	2.31 m	2.25 dt (12.0, 4.5)
H-6 β	1.31 m	1.26 m	1.33 m
H-7 α	2.33 m	2.37 m	2.31 dd (12.0, 5.5)
H-7 β	2.11 m	2.14 m	2.14 dd (12.0, 6.0)
H-9	2.60 q (9.4)	2.71 q (9.3)	2.68 q (10.0)
H-10 α	1.66 br t (9.0)	2.18 m	2.10 t (11.0)
H-10 β	1.66 br t (9.0)	1.84 dd (10.8, 8.7)	1.77 t (11.5)
H-12 α	1.26 m		
H-12 β	1.38 m		
H-13 α	1.97 q (8.0)	6.41 d (15.3)	2.43 m
H-13 β	1.97 q (8.0)		2.38 m
H-14	5.28 t (7.0)	6.97 d (15.3)	1.79 m, 1.84 m
H-15			4.89 br t (6.3)
H-16	4.13 2H, s	1.38 3H, s	1.23 3H, d (6.5)
H-17	1.78 3H, s	1.38 3H, s	
H-18	1.03 3H, s	1.32 3H, s	1.29 3H, s
H-19	4.86 1H, s	4.92 1H, s	4.92 1H, s
	4.97 1H, s	5.01 1H, s	5.01 1H, s
H-20	1.20 3H, s	1.22 3H, s	1.21 3H, s
Ac			2.02 3H, s

^a Spectra recorded at 300 MHz in CDCl₃ at 25 °C. ^b 500 MHz in CDCl₃ at 25 °C. ^c The *J* values (in parentheses) are in Hz.

Table 4. Cytotoxicity of Terpenoid Metabolites **1**–**6**^a

compd	cell lines ED ₅₀ (μ g/mL)					
	Hepa59T/VGH	KB	NCI-H661	Hela	Med	DLD-1
1	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0
2	18.5	>20.0	>20.0	>20.0	>20.0	16.9
3	4.6	7.3	– ^b	–	–	–
4	8.3	7.6	–	–	–	–
5	>20.0	19.5	19.0	15.9	>20.0	–
6	>20.0	>20.0	15.7	>20.0	>20.0	>20.0

^a Standard is doxorubicin with ED₅₀ values of 0.47, 0.25, 0.29, 0.41, 0.57, and 0.22 μ g/mL against Hepa59T/VGH, KB, NCI-H661, Hela, Med, and DLD-1, respectively. ^b Not tested.

at δ 2.02 (3H, s), it was found that there is only one secondary methyl attached at C-15 (δ 1.23, d, $J = 6.5$ Hz), thus indicating the norditerpenoid nature of **5**. The molecular framework of **5** was further confirmed by the observed COSY and HMBC correlations (Figure 1).

The relative stereochemistries at C-1, C-4, C-5, C-9, and C-11 in **5** were found to be the same as those of **3** on the basis of the NOE correlations observed in a NOESY spectrum (Figure 3). The chemical shifts of both C-1 protons in **4** (δ 2.46, t, $J = 9.7$ Hz) and **5** (δ 2.41, t, $J = 10.0$ Hz) were found to be close to that of **14** (δ 2.52, dd, $J = 10.0, 9.7$ Hz)¹² and are significantly downfield shifted in comparison with those of **3** (δ 1.83, t, $J = 9.6$ Hz) and **16** (δ 1.76, t, $J = 10.0$ Hz).¹¹ These data revealed that both C-1 protons of **4** and **5** are *syn* oriented relative to the carbonyl-containing substituents at C-10. From the above observations and other NOE interactions (Figure 3), the structure of nanolobatin C (**5**) ($[\alpha]_D +21.0^\circ$), which is produced together with **3** and **4** from the same organism, is thus elucidated as (1*S*,4*S*,5*S*,9*R*,11*S*)-4,5-epoxy-15-acetoxy-17-norxeniaphyll-8(19)-en-12-one.

In addition to the discovery of the above caryophyllene-based metabolites, two furanones, **6** and **7**, were also isolated. The structures of these two compounds were established by 1D and 2D NMR experiments. Compound **6** was obtained as a colorless oil, $[\alpha]_D^{25} +9.8^\circ$ (c 1.02,

CHCl₃). Its EIMS (*m/z* 128, [M]⁺) together with NMR data revealed the molecular formula C₆H₈O₃. Compound **6** was found to possess hydroxyl (IR ν_{\max} 3422 cm⁻¹; EIMS *m/z* 110 [M - H₂O]⁺) and ester carbonyl (IR ν_{\max} 1746 cm⁻¹; ¹³C NMR δ 172.5, C) moieties. A conjugated *cis*-1,2-disubstituted double bond was also assigned (¹³C NMR δ 122.1 (CH) and 158.1 (CH); ¹H NMR δ 6.12 and 7.38, each 1H, d, *J* = 5.7 Hz for both protons). Moreover, the ¹H NMR data of **6** showed two 1H doublet signals of an oxymethylene at δ 3.70 and 3.80 (each d, *J* = 12.0 Hz) and one 3H singlet of a tertiary methyl at δ 1.48, which were found to be correlated with the signals of the fully substituted oxycarbon at δ 89.3 (C) and the olefinic methine carbon at δ 158.1 in the HMBC spectrum (Figure 1). Comparison of NMR spectral data of **6** (see Experimental Section) with those of the known synthesized compound **15**¹⁹ established the identity of **6** and **15**. Therefore, on the basis of the sign of its optical activity, compound **6** was established as (+)-5-hydroxymethyl-5-methylfuran-2-one.

Furthermore, **7**, a less polar compound relative to **6**, was also obtained as a colorless oil, [α]_D²⁵ +21.4 (*c* 0.28, CHCl₃). Its IR spectrum indicated the absence of the hydroxyl and the presence of the ester carbonyl (ν_{\max} 1740 cm⁻¹). NMR spectral data (see Experimental Section) indicated that **7** is simply an acetylated derivative of **6**, as shown by the presence of additional carbon signals at δ 20.6 (CH₃) and 170.4 (C=O of ester) and a proton signal at δ 2.05 (3H, s, OCOCH₃). According to the sign of the optical rotation, the structure of **7** was thus established as (+)-5-acetoxymethyl-5-methylfuran-2-one.

It is noteworthy to mention that the novel metabolite **2** represents the first example of a 13-nor-9-*epi*- β -caryophyllene compound, and **5** is the first 17-norxeniaphyllane-based derivative reported. In contrast to the *trans* ring fused β -caryophyllenes, which are common natural metabolites, the caryophyllenes with a *cis* ring junction are rarely found.¹³⁻¹⁷ To the best of our knowledge, the norsesquiterpenoid **2** is the fourth natural product of this series and is the first one isolated from a marine organism. Moreover, we report the isolation of furanones **6** and **7** for the first time from natural sources.

The new terpenoid metabolites (**1-5**) and the furanone derivative **6** were evaluated for their *in vitro* cytotoxic activity against a limited panel of cancer cell lines. The results showed that the xeniaphyllane-type diterpenoids **3** and **4** exhibited moderate cytotoxicities against KB and Hepa59T/VGH cell lines (ED₅₀ values of 7.3 and 7.6 μ g/mL against the growth of KB cells and 4.5 and 8.3 μ g/mL against the growth of Hepa59T/VGH cells, respectively). Norditerpenoid **5** exhibited weak activity against Hela, NCI-H661, and KB cells (ED₅₀ values of 15.9, 19.0, and 19.5 μ g/mL, respectively) and was inactive toward Hepa59T/VGH and Med cell lines. It was also found that the *cis* ring fused β -caryophyllene-type norsesquiterpenoid **2** exhibited only weak cytotoxicity against DLD-1 and Hepa59T/VGH (ED₅₀ values of 16.9 and 18.5 μ g/mL, respectively), while the *trans* ring fused related metabolite **1** showed no activity against the above six cancer cell lines. Moreover, furanone **6** was found to show only weak activity against NC-H661 cancer cells, with a ED₅₀ value of 15.7 μ g/mL.

Experimental Section

General Experimental Procedures. Optical rotations were measured on a Jasco DIP-1000 digital polarimeter. IR spectra were recorded on a Jasco FT-5300 infrared spectrophotometer. NMR spectra were recorded on a Bruker Avance DPX300 FT-NMR at 300 MHz for ¹H and 75 MHz for ¹³C or on a Varian Unity INOVA 500 FT-NMR at 500 MHz for ¹H

and 125 MHz for ¹³C, respectively, in CDCl₃ using TMS as internal standard. EIMS was obtained with a VG Quattro GC/MS spectrometer. HRMS spectra were recorded on a Finnigan MAT-95XL mass spectrometer. Silica gel (Merck, 230-400 mesh) was used for column chromatography. Precoated silica gel plates (Merck, Kieselgel 60 F-254, 0.2 mm) were used for analytical TLC.

Organism. *S. nanolobata* was collected by hand via scuba off the coast of southern Pingtung, Taiwan, in February 2001, at a depth of 15-20 m, and stored in a freezer until extraction. A voucher sample was deposited at the Department of Marine Resources, National Sun Yat-Sen University (specimen no. SC003).

Extraction and Isolation. The lyophilized bodies of *S. nanolobata* (1.2 kg, wet wt) were minced and extracted exhaustively with *n*-hexane (1 L \times 5) and then with dichloromethane (0.4 L \times 3). The residue of dichloromethane layer was further extracted with *n*-hexane. The combined *n*-hexane extract was evaporated under vacuum to yield an oily residue (9.6 g), which was chromatographed over silica gel, using *n*-hexane, an *n*-hexane and EtOAc mixture of increasing polarity, then EtOAc-MeOH (stepwise, 100:0 to 50:50) to yield 28 fractions. Fraction 6, eluting with *n*-hexane-EtOAc (9:1), was chromatographed by normal-phase HPLC using a CH₂-Cl₂-MeOH gradient (99:1 to 97:3) to yield **5** (2.0 mg). Fraction 12, eluting with *n*-hexane-EtOAc (7:3), was purified by normal-phase HPLC using *n*-hexane-EtOAc (4:1) to afford **7** (2.5 mg). Fractions 13 and 14, eluting with *n*-hexane-EtOAc (1:1), were separately purified by normal-phase HPLC using *n*-hexane-EtOAc (3:1) to afford **4** (11.4 mg) and **3** (5.8 mg), respectively. Fraction 21, eluting with EtOAc, was further separated by normal-phase HPLC using *n*-hexane-acetone (4:1 to 3:1) to give **2** (10.2 mg), **1** (18.5 mg), and **6** (9.6 mg).

Nanonorcaryophyllene A (1): colorless oil; [α]_D²⁵ +42.6° (*c* 1.48, CHCl₃); IR (neat) ν_{\max} 3371, 2968, 2928, 2878, 1541, 1456, 1299, 1219 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) and ¹³C NMR (CDCl₃, 75 MHz), see Tables 1 and 3, respectively; EIMS *m/z* 222 (0.2, [M]⁺), 204 (0.3, [M - H₂O]⁺), 189 (0.8, [M - Me - H₂O]⁺), 149 (14.9), 121 (31.0); HREIMS *m/z* 222.1617 (calcd for C₁₄H₂₂O₂, 222.1622).

Nanonorcaryophyllene B (2): colorless oil; [α]_D²⁵ -7.6° (*c* 0.92, CHCl₃); IR (neat) ν_{\max} 3422, 2948, 2928, 2878, 1700, 1647, 1541, 1456 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) and ¹³C NMR (CDCl₃, 75 MHz), see Tables 1 and 3, respectively; EIMS *m/z* 222 (0.2, [M]⁺), 204 (1.1, [M - H₂O]⁺), 189 (2.2, [M - Me - H₂O]⁺), 149 (14.9), 161 (11.3), 146 (12.6), 131 (14.5); HREIMS *m/z* 222.1618 (calcd for C₁₄H₂₂O₂, 222.1622).

Nanolobatin A (3): colorless oil; [α]_D²⁵ +15.0° (*c* 1.60, CHCl₃); IR (neat) ν_{\max} 3437, 3011, 2981, 2934, 2874, 1632, 1454, 1381, 1373, 997, 896 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) and ¹³C NMR (CDCl₃, 75 MHz), see Tables 1 and 2, respectively; EIMS (30 eV) *m/z* 304 (0.2, [M]⁺), 286 (0.4, [M - H₂O]⁺), 271 (1.0, [M - Me - H₂O]⁺), 256 (0.8), 241 (0.6), 205 (2.7), 149 (11.7), 135 (12.4); HREIMS *m/z* 304.2404 (calcd for C₂₀H₃₂O₂, 304.2404).

Nanolobatin B (4): colorless oil; [α]_D²⁵ +66.7° (*c* 0.60, CHCl₃); IR (neat) ν_{\max} 3640, 3025, 2965, 2935, 2875, 1709, 1689, 1630, 1452, 1379, 1037, 902 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) and ¹³C NMR (CDCl₃, 75 MHz), see Tables 1 and 2, respectively; FABMS *m/z* 341 (0.4, [M + Na]⁺), 319 (0.2, [M + H]⁺), 304 (0.5, [M - Me + H]⁺), 301 (0.5, [M - H₂O + H]⁺), 286 (0.5, [M - Me - H₂O + H]⁺); HREIMS *m/z* 318.2394 (calcd for C₂₀H₃₀O₃, 318.2196).

Nanolobatin C (5): colorless oil; [α]_D²⁵ +21.0° (*c* 0.92, CHCl₃); IR (neat) ν_{\max} 2970, 2936, 2875, 1734, 1700, 1635, 1541, 1456, 1375, 1244, 1039, 960 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) and ¹³C NMR (CDCl₃, 100 MHz), see Tables 1 and 2, respectively; FABMS *m/z* 371 (2.0, [M + Na]⁺), 349 (5.5, [M + H]⁺), 289 (15.8, [M - AcOH + H]⁺), 154 (71.1); HREIMS *m/z* 288.2083 (calcd for C₂₁H₃₂O₄ - AcOH, 288.2084).

(+)-5-Hydroxymethyl-5-methylfuran-2-one (6): colorless oil; [α]_D²⁵ +9.8° (*c* 1.02, CHCl₃); IR (neat) ν_{\max} 3422, 2924, 2852, 1746, 1647, 1458, 1219, 1119, 1055, 956 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) 7.38 (1H, d, *J* = 5.7, H-4), 6.12 (1H, d, *J* = 5.7, H-3),

3.80 (1H, d, $J = 12.0$, H-7), 3.70 (1H, d, $J = 12.0$, H-7), 1.48 (3H, s, H₃-6); ¹³C NMR (CDCl₃, 75 MHz) 172.5 (C, C-5), 158.1 (CH, C-4), 122.1 (CH, C-3), 89.3 (C, C-5), 66.5 (CH₂, C-7), 20.1 (CH₃, C-6); EIMS m/z 128 (2.3, [M]⁺), 113 (0.5, [M - Me]⁺), 110 (1.8, [M - H₂O]⁺), 98 (100.0), 97 (83.4); HREIMS m/z 129.0549 (calcd for C₆H₉O₄, 129.0546).

(+)-5-Acetoxyethyl-5-methylfuran-2-one (7): colorless oil; $[\alpha]_D^{25} +21.5^\circ$ (c 0.28, CHCl₃); IR (neat) ν_{\max} 2955, 2926, 2866, 1740, 1659, 1611, 1458, 1375, 1165, 1020, 885, 814 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) 7.33 (1H, d, $J = 5.7$, H-4), 6.10 (1H, d, $J = 5.7$, H-3), 4.34 (1H, d, $J = 11.7$, H-7), 4.17 (1H, d, $J = 11.7$, H-7), 2.05 (3H, s, OCOCH₃), 1.15 (3H, s, H₃-6); ¹³C NMR (CDCl₃, 75 MHz) 171.8 (C, C-2), 170.4 (C, Ac-carbonyl), 156.9 (CH, C-4), 122.2 (CH, C-3), 86.8 (C, C-5), 65.8 (CH₂, C-7), 20.8 (CH₃, C-6), 20.6 (CH₃, Ac-Me); EIMS m/z 170 (0.1, [M]⁺), 155 (1.5, [M - Me]⁺), 134 (58.1), 110 (3.4, [M - AcOH]⁺), 98 (100.0).

Cytotoxicity Testing. Cell lines were purchased from the American Type Culture Collection (ATCC). Cytotoxicity assays of the test compounds 1–5 and 7 were performed using the MTT [3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide] colorimetric method.^{20,21}

Acknowledgment. This work was supported by a grant from the National Science Council of the Republic of China (Contract No. NSC-90-2323-B-110-003) awarded to J.-H.S.

References and Notes

- Faulkner, D. *J. Nat. Prod. Rep.* **2002**, *19*, 1–48, and previous reports in this series.
- Sheu, J.-H.; Ahmed, A. F.; Shiue, R.-T.; Dai, C.-F.; Kuo, Y.-H. *J. Nat. Prod.* **2002**, *65*, 1904–1908, and references therein.
- Yamada, K.; Ujie, T.; Yoshida, K.; Miyamoto, T.; Higuchi, R. *Tetrahedron* **1997**, *53*, 4569–4578.
- Sheu, J.-H.; Sung, P.-J.; Su, J.-H.; Duh, C.-Y.; Chiang, M. Y. *Tetrahedron* **1999**, *55*, 14555–14564.
- Sheu, J.-H.; Chen S.-P.; Sung, P.-J.; Chiang, M. Y.; Dai, C.-F. *Tetrahedron Lett.* **2000**, *41*, 7885–7888.
- Sung, P.-J.; Su, J.-H.; Duh, C.-Y.; Chiang, M. Y.; Sheu, J.-H. *J. Nat. Prod.* **2001**, *64*, 318–323.
- Wang, G.-H.; Ahmed, A. F.; Sheu, J.-H.; Duh, C.-Y.; Shen, Y.-C.; Wang, L.-T. *J. Nat. Prod.* **2002**, *65*, 887–891.
- Ahond, A.; Bowden, B. F.; Coll, J. C.; Fourneron, J.-D.; Mitchell, S. *J. Aust. J. Chem.* **1981**, *34*, 2657–2664.
- Groweiss, A.; Kashman, Y. *Tetrahedron* **1983**, *39*, 3385–3396, and references therein.
- König, G. M.; Wright, A. D. *J. Nat. Prod.* **1993**, *56*, 2198–2200.
- Thebtaranonth, C.; Thebtaranonth, Y.; Wanauppathamkul, S.; Yuthavong, Y. *Phytochemistry* **1995**, *40*, 125–128.
- Abraham, W.-R.; Ernst, L.; Stumpf, B. *Phytochemistry* **1990**, *29*, 115–120.
- Bohlmann, F.; Zdero, C. *Phytochemistry* **1978**, *17*, 1135–1153.
- Bohlmann, F.; Ziesche, J. *Phytochemistry* **1981**, *20*, 469–472.
- Berry, K. M.; Perry, N. B.; Weavers, R. T. *Phytochemistry* **1985**, *24*, 2893–2898.
- Hinkley, S. F. R.; Perry, N. B.; Weavers, R. T. *Phytochemistry* **1994**, *35*, 1489–1494.
- Barrero, A. F.; Sánchez, J. F.; Ferrol, N. *Tetrahedron Lett.* **1989**, *30*, 247–250.
- Demirci, B.; Baser, K. H. C.; Demirci, F.; Hamann, M. T. *J. Nat. Prod.* **2000**, *63*, 902–904.
- Ohe, K.; Takahashi, H.; Uemura, S.; Sugita, N. *J. Org. Chem.* **1987**, *52*, 4859–4863.
- Alley, M. C.; Scudiero, D. A.; Monks, A.; Hursey, M. L.; Czerwinski, M. J.; Fine, D. L.; Abbott, B. J.; Mayo, J. G.; Shoemaker, R. H.; Boyd, M. R. *Cancer Res.* **1988**, *48*, 589–601.
- Scudiero, D. A.; Shoemaker, R. H.; Paull, K. D.; Monks, A.; Tierney, S.; Nofziger, T. H.; Currens, M. J.; Seniff, D.; Boyd, M. R. *Cancer Res.* **1988**, *48*, 4827–4833.

NP030286W